Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03499821
NCT03499821CompletedNot Applicable

A Multicenter Clinical Evaluation of the Clinical Performance of a Phakic Intraocular Lens

Staar Surgical Company6 sites in 2 countries41 target enrollmentStarted: March 20, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
41
Locations
6
Primary Endpoint
Number of Eyes With Monocular Uncorrected Near Visual Acuity of 20/40 or Better at 40 cm 6 Months After Implantation
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study will evaluate the clinical performance of a phakic intraocular lens (IOL) for the improvement of Uncorrected Near Visual Acuity (UCNVA) in subjects who require between +1.00 and +2.50 Reading Add.

Detailed Description

This is a prospective, open-labeled, multi-site evaluation of clinical performance of the STAAR EVO+ Visian™ Implantable Collamer® Lens (VICL) with Aspheric (EDOF) Optic [EDOF ICL] for the improvement of UCNVA in subjects who require between +1.00 and +2.50 Reading Add.

Approximately 48 subjects who meet all eligibility criteria will undergo EDOF ICL implantation in both eyes. All eyes will be followed for 6 months after surgery.

The first eye implanted with the study lens and the appropriate time for fellow eye implantation will be determined by the medical judgement of the Investigator. All eyes will be analyzed for safety and performance.

The primary performance endpoint is defined as achievement of monocular UCNVA of Snellen equivalent 20/40 or better at 40 cm at 6 months after implantation in equal to or greater than 75% of implanted eyes.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
40 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Must be able to read, understand and provide written informed consent,
  • •Willing and able to comply with all treatment and follow-up study related procedures,
  • •40 - 60 years of age at time of surgery if require spherical lens powers from -0.50 D to -18.00 D,
  • •35 - 45 years of age at time of surgery if require a spherical lens power from 0.0 D to +3.00 D,
  • •Preoperative refraction fully correctable with available lens powers, with ≤ 0.75 D preoperative refractive and residual cylinder,
  • •< 0.75 D spherical equivalent difference between cycloplegic and manifest refractions,
  • •Stable correction (± 0.50 D) as determined by manifest refraction spherical equivalent (MRSE),
  • •Best Corrected Distance Visual Acuity 20/20 or better in both eyes,
  • •Requires +1.00 D to +2.50 D reading add,
  • •Anterior chamber depth (ACD) ≥ 2.8 mm if require spherical lens powers from -0.50 D to -18.00 D,
  • •ACD ≥ 3.0 mm if require spherical lens powers from 0.00 D to +3.00 D,
  • •Anterior chamber angle ≥ Grade III,
  • •Phakic in both eyes,
  • •Current contact lens wearers need to demonstrate a stable refraction, (± 0.5 D), expressed as MRSE, on two consecutive examination dates with refractive stability determined by the following criteria:
  • •contact lenses were not worn for at least 2 weeks (rigid and toric contact lenses) or 3 days (soft contact lenses) prior to the first refraction,
  • •two refractions were performed at least 7 days apart.

Exclusion Criteria

  • •Participation in a clinical trial within 30 days prior to entry into this study and/or during the period of study participation,
  • •Previous intraocular or corneal surgery in either eye, including refractive surgery,
  • •Progressive sight threatening disease or other previous or current ocular conditions, other than myopia in either eye,
  • •Low/abnormal corneal endothelial cell density,
  • •Presence of active or history of chronic inflammation in either eye,
  • •Clinically significant irregular astigmatism in either eye,
  • •Serious, acute, chronic or systemic, non-ophthalmic disease or illness that would increase the operative risk, confound the outcome(s) of the study or which may preclude study completion,
  • •Use of topical steroids at time of implantation,
  • •Systemic or topical medication, other than prescribed study medications that may confound the outcome or increase the risk to the subject,
  • •Allergy to anesthetics or other postoperative medications required in this study,
  • •Subject who is pregnant, plans to become pregnant, or is lactating during the course of the study, or has another condition associated with the fluctuation of hormones that could lead to refractive changes,
  • •Subjects who present any emotional, physiologic, or anatomical condition which may preclude study participation.

Arms & Interventions

Study population

Experimental

EDOF ICL implanted into both eyes of eligible subjects.

Intervention: EDOF ICL (Device)

Outcomes

Primary Outcomes

Number of Eyes With Monocular Uncorrected Near Visual Acuity of 20/40 or Better at 40 cm 6 Months After Implantation

Time Frame: 6 months

Number of Eyes with Monocular Uncorrected Near Visual Acuity of 20/40 or better at 40 cm six months after implantation

Secondary Outcomes

  • Change From Baseline in Monocular Uncorrected Intermediate Visual Acuity at 80 cm 3 Months Post Implantation(Baseline and 3 months)
  • Change From Baseline in Monocular Uncorrected Intermediate Visual Acuity at 80 cm 1 Month Post Implantation(Baseline and 1 month)
  • Change From Baseline in Monocular Uncorrected Near Visual Acuity at 40 cm 1 Month Post Implantation(Baseline and 1 month)
  • Change From Baseline in Monocular Distance Corrected Intermediate Visual Acuity at 80 cm 1 Month Post Implantation(Baseline and 1 month)
  • Change From Baseline in Monocular Distance Corrected Near Visual Acuity at 40 cm 3 Months Post Implantation(Baseline and 3 months)
  • Change From Baseline in Binocular Uncorrected Near Visual Acuity at 40 cm 6 Months Post Implantation(Baseline and 6 months)
  • Change From Baseline in Binocular Uncorrected Near Visual Acuity at 40 cm 1 Month Post Implantation(Baseline and 1 month)
  • Percentage of Implanted Eyes Achieving Monocular Uncorrected Near Visual Acuity of 20/40 or Better at 40 cm 1 Month After Implantation(1 month)
  • Percentage of Implanted Eyes Achieving Monocular Uncorrected Near Visual Acuity of 20/40 or Better at 40 cm 3 Months After Implantation(3 months)
  • Change From Baseline in Monocular Uncorrected Near Visual Acuity at 40 cm 3 Months Post Implantation(Baseline and 3 months)
  • Change From Baseline in Monocular Uncorrected Near Visual Acuity at 40 cm 6 Months Post Implantation(Baseline and 6 months)
  • Change From Baseline in Monocular Distance Corrected Intermediate Visual Acuity at 80 cm 3 Months Post Implantation(Baseline and 3 months)
  • Change From Baseline in Monocular Distance Corrected Intermediate Visual Acuity at 80 cm 6 Months Post Implantation(Baseline and 6 months)
  • Change From Baseline in Monocular Distance Corrected Near Visual Acuity at 40 cm 1 Month Post Implantation(Baseline and 1 month)
  • Change From Baseline in Monocular Distance Corrected Near Visual Acuity at 40 cm 6 Months Post Implantation(Baseline and 6 months)
  • Change From Baseline in Binocular Uncorrected Near Visual Acuity at 40 cm 3 Months Post Implantation(Baseline and 3 months)
  • Change From Baseline in Monocular Uncorrected Intermediate Visual Acuity at 80 cm 6 Months Post Implantation(Baseline and 6 months)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (6)

Loading locations...

Similar Trials

Unknown
Not Applicable
The OPTICA Study - The Optimised Computed Tomography Pulmonary Angiography (CTPA) in Pregnancy, Quality and Safety StudyPregnancy RelatedVenous ThromboembolismPulmonary Embolism
NCT04179487University College Dublin464
Completed
Not Applicable
Clinical Investigation of the Multifocal IOL POD F GF in Cataracteous EyesLens OpacitiesCataractPresbyopia
NCT04699266Beaver-Visitec International, Inc.23
Completed
Not Applicable
Clinical Evaluation of Multifocal Intraocular Lens: OPTIVIS.TMCataract SenileLenses, Intraocular
NCT03512626Parc de Salut Mar32
Completed
Not Applicable
Clinical Investigation of the AcrySof IQ Vivity Extended Vision Intraocular Lens (IOL)Aphakia
NCT04098367Alcon Research222
Unknown
Not Applicable
To Evaluate IOL Position, Clinical Outcome of PanOptix in High Myopic Cataract PatientsCataractHigh Myopia
NCT05042856Wenzhou Medical University20
Clinical Performance of a Phakic... | Clinical Trial